Advertisement
"Doug brings more than thirty years of experience supporting new drugapprovals and product launches for many of the pharmaceutical industry'sleading companies," said Dr. Francois Nader, executive vice president andchief operating officer of NPS, to whom Mr. Dobak will report. "His expertisein regulatory affairs and knowledge of multiple therapeutic areas, includinggastrointestinal disorders, will be invaluable as we work to advance our late-stage product candidates, GATTEX and PREOS. In particular, Doug has playedimportant roles in the approval and launch of Propulsid and Nexium and lineextensions for Prilosec that will be helpful as we continue our work in thetreatment of gastrointestinal disorders with GATTEX."
Advertisement
About NPS
NPS Pharmaceuticals is a biopharmaceutical company focused on thedevelopment and commercialization of small molecules and recombinant proteinsas drugs, primarily for the treatment of metabolic, bone and mineral, andcentral nervous system disorders. The company has drug candidates in variousstages of clinical development. Additional information is available on thecompany's website, http://www.npsp.com.
Note: Statements made in this press release, which are not historical innature, constitute forward-looking statements for purposes of the safe harborprovided by the Private Securities Litigation Reform Act of 1995. Thesestatements are based on management's current expectations and beliefs and aresubject to a number of factors and uncertainties that could cause actualresults to differ materially from those described in the forward-lookingstatements. All information in this press release is as of October 30, 2007and we undertake no duty to update this information. A more completedescription of these risks can be found in our filings with the Securities andExchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2007.
SOURCE NPS Pharmaceuticals, Inc.
